Cargando…

Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study

BACKGROUND AND OBJECTIVE: Patients with cancer taking oral antineoplastic medications may encounter problems including suboptimal adherence as well as physical and psychological disease burden. Despite increase in the use of oncology pharmacy services, there are wide variations between healthcare pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Meng-Jung, Hsu, Han-Lin, Chang, Chia-Lun, Wang, Jou-Han, Kuo, Chun-Nan, Hsin, Yen-Chun, Chang, Elizabeth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228791/
https://www.ncbi.nlm.nih.gov/pubmed/37252908
http://dx.doi.org/10.1371/journal.pone.0286333
_version_ 1785051051994382336
author Wen, Meng-Jung
Hsu, Han-Lin
Chang, Chia-Lun
Wang, Jou-Han
Kuo, Chun-Nan
Hsin, Yen-Chun
Chang, Elizabeth H.
author_facet Wen, Meng-Jung
Hsu, Han-Lin
Chang, Chia-Lun
Wang, Jou-Han
Kuo, Chun-Nan
Hsin, Yen-Chun
Chang, Elizabeth H.
author_sort Wen, Meng-Jung
collection PubMed
description BACKGROUND AND OBJECTIVE: Patients with cancer taking oral antineoplastic medications may encounter problems including suboptimal adherence as well as physical and psychological disease burden. Despite increase in the use of oncology pharmacy services, there are wide variations between healthcare professionals and patient perceptions of patients’ medication experiences. The objective of the study was to explore the medication experience of taking oral targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). METHOD: We purposively sampled advanced stage (stage III or IV) NSCLC patients taking epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in a medical center in Taiwan. Face-to-face interviews using semi-structured interview guides were conducted. Interviews were transcribed verbatim and thematic analysis was applied. A phenomenological methodology was adopted to explore the underlying meaning of patients’ lived experience. RESULTS: A total of 19 participants with a mean age of 68.2 years were interviewed. The duration of EGFR-TKIs use ranged from 2 weeks to 5 years. When first learned about the unexpected yet ‘treatable’ cancer, participants expressed strong emotional responses based on their intrinsic beliefs of the terminal disease and therapy. They walked along an unfamiliar trail while confronting physical and psychological challenges and made compromises to treatment. Gaining experiences from cancer journey, patients with cancer continuously seek the ultimate goals–‘return to normal’. CONCLUSIONS: This study also revealed medication experiences of participants’ journey from seeking information in the initial phase and living with cancer, to taking back control of their own lives. Healthcare professionals could better empathize with patients’ loss of control and understand their perspectives when making clinical decisions. These findings can guide interdisciplinary teams to integrate patients’ beliefs and conduct pre-screening assessments of health literacy levels to tailor communication. Subsequent interventions should be developed to identify barriers to medication self-management and empower patients by building social networks.
format Online
Article
Text
id pubmed-10228791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-102287912023-05-31 Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study Wen, Meng-Jung Hsu, Han-Lin Chang, Chia-Lun Wang, Jou-Han Kuo, Chun-Nan Hsin, Yen-Chun Chang, Elizabeth H. PLoS One Research Article BACKGROUND AND OBJECTIVE: Patients with cancer taking oral antineoplastic medications may encounter problems including suboptimal adherence as well as physical and psychological disease burden. Despite increase in the use of oncology pharmacy services, there are wide variations between healthcare professionals and patient perceptions of patients’ medication experiences. The objective of the study was to explore the medication experience of taking oral targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). METHOD: We purposively sampled advanced stage (stage III or IV) NSCLC patients taking epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in a medical center in Taiwan. Face-to-face interviews using semi-structured interview guides were conducted. Interviews were transcribed verbatim and thematic analysis was applied. A phenomenological methodology was adopted to explore the underlying meaning of patients’ lived experience. RESULTS: A total of 19 participants with a mean age of 68.2 years were interviewed. The duration of EGFR-TKIs use ranged from 2 weeks to 5 years. When first learned about the unexpected yet ‘treatable’ cancer, participants expressed strong emotional responses based on their intrinsic beliefs of the terminal disease and therapy. They walked along an unfamiliar trail while confronting physical and psychological challenges and made compromises to treatment. Gaining experiences from cancer journey, patients with cancer continuously seek the ultimate goals–‘return to normal’. CONCLUSIONS: This study also revealed medication experiences of participants’ journey from seeking information in the initial phase and living with cancer, to taking back control of their own lives. Healthcare professionals could better empathize with patients’ loss of control and understand their perspectives when making clinical decisions. These findings can guide interdisciplinary teams to integrate patients’ beliefs and conduct pre-screening assessments of health literacy levels to tailor communication. Subsequent interventions should be developed to identify barriers to medication self-management and empower patients by building social networks. Public Library of Science 2023-05-30 /pmc/articles/PMC10228791/ /pubmed/37252908 http://dx.doi.org/10.1371/journal.pone.0286333 Text en © 2023 Wen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wen, Meng-Jung
Hsu, Han-Lin
Chang, Chia-Lun
Wang, Jou-Han
Kuo, Chun-Nan
Hsin, Yen-Chun
Chang, Elizabeth H.
Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title_full Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title_fullStr Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title_full_unstemmed Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title_short Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
title_sort understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: a phenomenological study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228791/
https://www.ncbi.nlm.nih.gov/pubmed/37252908
http://dx.doi.org/10.1371/journal.pone.0286333
work_keys_str_mv AT wenmengjung understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT hsuhanlin understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT changchialun understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT wangjouhan understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT kuochunnan understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT hsinyenchun understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy
AT changelizabethh understandingthemedicationexperienceofpatientswithadvancednonsmallcelllungcancertakingepidermalgrowthfactorreceptortyrosinekinaseinhibitorsaphenomenologicalstudy